MedTrace Logo

Case-Control Viramune (Nevirapine) Toxicogenomics Study

NCT00310843 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 889

Last updated 2013-08-01

No results posted yet for this study

Summary

Attempt to identify genetic polymorphisms in interrogated pathways which may be associated with symptomatic hepatotoxicity or severe cutaneous toxicity observed in case patients within the first 8 weeks of nevirapine therapy.

Conditions

  • HIV Infections

Interventions

DRUG

Nevirapine

Patients with HIV-1 infection who have taken or are currently taking nevirapine

Sponsors & Collaborators

Principal Investigators

  • Boehringer Ingelheim · Boehringer Ingelheim

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-02-28
Primary Completion
2008-09-30

Countries

  • United States
  • Argentina
  • Australia
  • Canada
  • France
  • Germany
  • Netherlands
  • Spain
  • Taiwan
  • Thailand
  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00310843 on ClinicalTrials.gov